NASDAQ$STTK
Shattuck Labs In · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business highlights.
Shattuck Labs reported fourth quarter revenue of $30.1 million and net income of $7.8 million, or $0.19 per basic share and $0.18 per diluted share. The company's cash, cash equivalents and short-term investments were $268.8 million as of December 31, 2021.
- Presented positive initial dose-escalation clinical data for SL-172154, including high target occupancy, dose-dependent immune activation, and unique safety profile in heavily pretreated cancer patients.
- Presented positive initial dose-escalation clinical data for SL-279252, including anti-tumor activity, high target occupancy, and dose-dependent immune activation in heavily pretreated cancer patients.
- Announced Initial Data from SL-172154 Phase 1 Dose-Escalation Clinical Trial in Platinum- Resistant Ovarian Cancer Demonstrating Favorable Safety Profile, High Target Occupancy, and Unique Pharmacodynamic Activity at the 36th Annual SITC Meeting
- Announced Initial Data from Ongoing SL-279252 Phase 1 Dose-Escalation Clinical Trial in Advanced Solid Tumors Demonstrating Evidence of Anti-Tumor Activity and Dose-Dependent Pharmacodynamic Activity at the 36th Annual SITC Meeting
Headline financials
Revenue & EPS history
Shattuck Labs · Revenue · Quarterly
$30.1M
Forward guidance
Shattuck believes its cash, cash equivalents and short-term investments will be sufficient to fund its operations into the second half of 2024, which is beyond results from its Phase 1 clinical trials of SL-172154 and SL-279252.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
-2.3%
Avg return
Earnings day
-3.1%
Avg return
5 days after
-1.1%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+10.7%
Q2 2020
Best reaction
-34.2%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -6.4% | -0.9% | -31.6% | |
| Q4 2025 | +7.8% | +26.0% | +35.7% | |
| Q3 2025 | -4.5% | -2.9% | +52.0% | |
| Q1 2025 | -0.1% | -3.7% | +21.3% | |
| Q4 2024 | -7.0% | -13.7% | -30.2% | |
| Q3 2024 | +1.6% | -6.6% | -6.6% | |
| Q2 2024 | -8.3% | -22.4% | -9.8% | |
| Q1 2024 | -0.7% | -1.0% | -32.0% | |
| Q4 2023 | +7.3% | +6.3% | -0.6% | |
| Q3 2023 | -22.4% | -12.2% | +0.0% | |
| Q2 2023 | -10.7% | -11.1% | -9.1% | |
| Q1 2023 | +3.3% | -3.7% | +8.6% | |
| Q4 2022 | +4.8% | +8.5% | -30.3% | |
| Q3 2022 | -12.2% | -6.8% | -0.4% | |
| Q2 2022 | -2.8% | +1.3% | -17.3% | |
| Q1 2022 | +4.9% | -0.9% | +27.3% | |
| Q4 2021 | +10.3% | +22.4% | -13.1% | |
| Q3 2021 | -34.2% | -34.5% | -51.8% | |
| Q2 2021 | +1.2% | -1.5% | -1.4% | |
| Q1 2021 | -3.5% | -9.2% | -2.7% | |
| Q4 2020 | -2.5% | -13.8% | -13.3% | |
| Q3 2020 | +10.7% | +4.9% | +40.2% | |
| Q2 2020 | +10.7% | +4.9% | +40.2% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro